+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Myositis Drug"

Myositis - Pipeline Insight, 2024 - Product Thumbnail Image

Myositis - Pipeline Insight, 2024

  • Drug Pipelines
  • November 2024
  • 80 Pages
  • Global
From
Inclusion Body Myositis - Pipeline Insight, 2025 - Product Thumbnail Image

Inclusion Body Myositis - Pipeline Insight, 2025

  • Drug Pipelines
  • March 2025
  • 60 Pages
  • Global
From
From
From
From
Sporadic Inclusion Body Myositis (sIBM) - Pipeline Insight, 2024 - Product Thumbnail Image

Sporadic Inclusion Body Myositis (sIBM) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
  • 8 Results (Page 1 of 1)
Loading Indicator

Myositis is a type of immune disorder that affects the muscles and is characterized by muscle inflammation and weakness. Treatment for myositis typically involves a combination of medications, physical therapy, and lifestyle changes. Drugs used to treat myositis include corticosteroids, immunosuppressants, and biologics. Corticosteroids are used to reduce inflammation and pain, while immunosuppressants are used to reduce the activity of the immune system. Biologics are used to target specific proteins that are involved in the inflammation process. The myositis drug market is a rapidly growing segment of the immune disorder drugs market. It is driven by the increasing prevalence of myositis, the development of new drugs, and the increasing demand for personalized treatments. Companies in the myositis drug market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more